AP
NVO

Anchyra Partners’s Novo Nordisk NVO Stock Holding History

Anchyra Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$369K Buy
7,699
+1,593
+26% +$68.4K 0.09% 204
2026
Q1 		$224K Buy
6,106
+389
+7% +$18.4K 0.07% 254
2025
Q4 		$291K Buy
+5,717
New +$292K 0.09% 196

Other funds holding NVO

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
MG
Markel Group Glen Allen, Virginia $13.1B AUM 15.62% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return

Anchyra Partners's NVO Position: Q2 2026 in Review

Anchyra Partners increased its Novo Nordisk (NVO) stake by 26% in Q2 2026, buying an estimated $68.4K and bringing the position to 7,699 shares worth $369K. The position accounts for 0.09% of the portfolio, ranked #204.

Anchyra Partners first reported a position in NVO in Q4 2025 and has held it in 3 quarters since. 819 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Anchyra Partners held 7,699 shares of Novo Nordisk worth $369K as of Q2 2026.
  • Anchyra Partners bought 1,593 Novo Nordisk shares in Q2 2026, an estimated $68.4K.
  • Novo Nordisk made up 0.09% of Anchyra Partners's portfolio in Q2 2026, its #204 holding.
  • Anchyra Partners first reported a position in Novo Nordisk in Q4 2025 and has held it in 3 quarters since.
  • 819 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Anchyra Partners's 13F filing for Q2 2026, filed 23 Jul 2026.